AJ Lanigan: Indeed. In reality, pharma businesses are earning significant dollars with treatment plans like Keytruda and Opdivo that deal with PD-one and PD-L1. Right here’s the super interesting element: think of checkpoints as website traffic signals. You don’t want an immune procedure that’s working wild just like a freight prepare above a